Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

Biopharma enters 2026 amid continuing scientific progress and accelerating deal activity, yet its business model is under pressure across every facet of the value chain. Investors are taking note: ...

The global life sciences industry has accelerated dealmaking activity with mergers and acquisitions (M&A) investment totaling ...

Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.NVIDIA collaborates with Thermo Fisher to ...

("BrightInsight"), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, highlighting the positive impact of the Patient App on ...

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination ...

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, announced today that Ricardo ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

Discover how advanced detectors are driving improvements in biopharma quality assurance by enhancing precision across ...

Drug distributor Cardinal Health raised its 2026 profit forecast on Tuesday, driven ​by robust demand for specialty medicines ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...